A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.Multiple sclerosis (MS) is a chronic and progressive neurological disease characterized by recurrent episodes of inflammatory demyelination of the brain and spinal cord.  Alemtuzumab has been previously shown in large phase III trials to be an effective therapy in reducing MS clinical flares as well as new radiological activity and atrophy rates.  The purpose of this study was to examine real-world effectiveness and safety data from a large cohort of people treated with alemtuzumab at an academic medical center, including those who failed B-cell depletion therapy.  We compare and contrast our results to other available real-world data using alemtuzumab in multiple sclerosis.
alemtuzumab
A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.Multiple sclerosis (MS) is a chronic and progressive neurological disease characterized by recurrent episodes of inflammatory demyelination of the brain and spinal cord.  Alemtuzumab has been previously shown in large phase III trials to be an effective therapy in reducing MS clinical flares as well as new radiological activity and atrophy rates.  The purpose of this study was to examine real-world effectiveness and safety data from a large cohort of people treated with alemtuzumab at an academic medical center, including those who failed B-cell depletion therapy.  We compare and contrast our results to other available real-world data using alemtuzumab in multiple sclerosis.
alemtuzumab
A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.Multiple sclerosis (MS) is a chronic and progressive neurological disease characterized by recurrent episodes of inflammatory demyelination of the brain and spinal cord.  Alemtuzumab has been previously shown in large phase III trials to be an effective therapy in reducing MS clinical flares as well as new radiological activity and atrophy rates.  The purpose of this study was to examine real-world effectiveness and safety data from a large cohort of people treated with alemtuzumab at an academic medical center, including those who failed B-cell depletion therapy.  We compare and contrast our results to other available real-world data using alemtuzumab in multiple sclerosis.
alemtuzumab
A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.Multiple sclerosis (MS) is a chronic and progressive neurological disease characterized by recurrent episodes of inflammatory demyelination of the brain and spinal cord.  Alemtuzumab has been previously shown in large phase III trials to be an effective therapy in reducing MS clinical flares as well as new radiological activity and atrophy rates.  The purpose of this study was to examine real-world effectiveness and safety data from a large cohort of people treated with alemtuzumab at an academic medical center, including those who failed B-cell depletion therapy.  We compare and contrast our results to other available real-world data using alemtuzumab in multiple sclerosis.
alemtuzumab